文献速递胸部肿瘤

循环内皮细胞微粒预测晚期肺癌疗效

[Circulating endothelial microparticles for prediction of therapeutic effect in advanced lung cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

该研究纳入88例晚期肺癌患者,检测治疗前CD105+内皮细胞微粒(EMPs)与乳酸脱氢酶(LDH),发现CD105+EMPs≥70 events/μl和LDH可预测疾病进展,联合模型AUC为0.729。结论提示CD105+EMPs联合LDH有助于预测晚期肺癌疗效。

要点

  • CD105+EMPs≥70 events/μl与晚期肺癌进展风险独立相关(OR=3.623)。
  • CD105+EMPs联合LDH预测进展模型AUC=0.729,特异度91.6%。
  • 治疗前检测CD105+EMPs或可辅助识别疗效不佳的高危患者。

核心结论

  • CD105+EMPs与晚期肺癌进展相关,联合LDH能够预测晚期肺癌的疗效。

研究设计与样本

  • 回顾性收集2018年10月至2019年5月解放军总医院第一医学中心肿瘤科88例晚期肺癌患者资料,检测治疗前血常规、LDH、肿瘤标志物及CD105+EMPs,采用流式细胞仪检测CD105+EMPs数目,多因素logistic回归分析进展预测指标。

主要发现

  • 88例患者中客观反应组60例,疾病进展组28例,两组性别、年龄、基础疾病史、肿瘤分期、肿瘤类型、治疗方案差异均无统计学意义(均P>0.05)。
  • 两组细胞角蛋白19片段、神经元特异性烯醇化酶、LDH、总微粒(MPs)、CD105+EMPs差异均有统计学意义(均P<0.05)。
  • 多因素logistic回归显示CD105+EMPs≥70 events/μl(OR=3.623,95%CI为1.345~9.761,P=0.011)和LDH(OR=1.008,95%CI为1.001~1.015,P=0.032)能够预测晚期肺癌进展。
  • 基于多因素回归建立的预测模型AUC为0.729(95%CI为0.620~0.837,P=0.001),敏感度32.1%,特异度91.6%,阳性预测值64.2%,阴性预测值74.3%。

关键数值与推荐

  • CD105+EMPs≥70 events/μl预测晚期肺癌进展的OR=3.623(95%CI为1.345~9.761,P=0.011)。
  • LDH预测晚期肺癌进展的OR=1.008(95%CI为1.001~1.015,P=0.032)。
  • 预测模型AUC=0.729(95%CI为0.620~0.837,P=0.001),敏感度32.1%,特异度91.6%,阳性预测值64.2%,阴性预测值74.3%。

临床怎么用

  • 对晚期肺癌患者,治疗前可检测CD105+EMPs和LDH,若CD105+EMPs≥70 events/μl或LDH升高,提示进展风险较高,可加强监测或考虑更积极治疗策略。

局限性

  • 研究为单中心回顾性分析,样本量88例,结论需更大规模前瞻性研究验证。
  • 预测模型敏感度32.1%较低,单独用于筛查进展可能漏诊较多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the correlation of endothelial microparticles and progression of advanced lung cancer, and its predictive value in therapeutic effect. Methods: The data of patients with advanced lung cancer in the Oncology Department of Frist Medical Center of Chinese PLA General Hospital from October 2018 to May 2019 were collected. Blood routine, lactate dehydrogenase (LDH), tumor markers, and circulating endothelial microparticles (CD105+ EMPs) were measured before treatment. Flow cytometry was used to detect the number of CD105+ EMPs, and multivariate regression analysis was used to study the predict factors of advanced lung cancer progression. Results: A total of 88 patients were recruited in the study, including 60 in the objective response (OR) group and 28 in the disease progression (PD) group. There were no significant differences in gender, age, basic diseases, tumor stage, cancer type and therapeutic intervention between two groups, while there were significant differences in tumor marker, LDH, total microparticles (MPs), and endothelial microparticles (CD105+ EMPs) between two groups (P<0.05). In the multivariate regression analysis, CD105+ EMPs ≥70 events/μl (OR=3.623, 95%CI=1.345~9.761, P=0.011) and LDH (OR=1.008, 95%CI=1.001~1.015, P=0.032) were able to predict the progression of advanced lung cancer. A predictive model of advanced lung cancer progression was established based on the multivariate regression results. The area under the receiver operating characteristic curve (AUC) was 0.729 (95%CI=0.620~0.837, P=0.001), the sensitivity was 32.1%, the specificity was 91.6%, the positive predictive value was 64.2%, and the negative predictive value was 74.3%. Conclusion: Circulating endothelial microparticles are associated with the progression of advanced lung cancer, it combined with LDH can predict the therapeutic effect of advanced lung cancer. 目的: 探讨循环血内皮细胞微粒(EMPs)与晚期肺癌疾病进展(PD)的关系及其对疗效的预测价值。 方法: 收集2018年10月至2019年5月解放军总医院第一医学中心肿瘤科常规治疗的88例晚期肺癌患者资料,检测治疗前血常规、乳酸脱氢酶(LDH)、肿瘤标志物以及CD105+EMPs的表达情况。采用流式细胞仪检测CD105+EMPs数目,采用多因素logistic回归分析晚期肺癌进展的预测指标。 结果: 88例晚期肺癌患者中,客观反应组60例,PD组28例。两组患者的性别、年龄、基础疾病史、肿瘤分期、肿瘤类型、治疗方案等差异均无统计学意义(均P>0.05),两组患者细胞角蛋白19片段、神经元特异性烯醇化酶、LDH、总微粒(MPs)、CD105+EMPs的差异均有统计学意义(均P<0.05)。logistic多因素回归分析结果显示,CD105+EMPs≥70 events/μl(OR=3.623,95%CI为1.345~9.761,P=0.011)和LDH(OR=1.008,95%CI为1.001~1.015,P=0.032)能够预测晚期肺癌的进展。根据多因素回归分析结果建立预测晚期肺癌进展模型,受试者工作特征曲线示,曲线下面积为0.729(95%CI为0.620~0.837,P=0.001),敏感度为32.1%,特异度为91.6%,阳性预测值为64.2%,阴性预测值为74.3%。 结论: CD105+EMPs与晚期肺癌进展相关,CD105+EMPs联合LDH能够预测晚期肺癌的疗效。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu TT, Wang J, Cui PF, et al. [Circulating endothelial microparticles for prediction of therapeutic effect in advanced lung cancer]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32988153. doi:10.3760/cma.j.cn112152-20200317-00214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。